Invitation to Dynavox Group’s webcast following the 2025 year-end report

Dynavox Group AB (Nasdaq Stockholm: DYVOX) will publish its 2025 year-end report on 5 February 2026 at 07:30 CET, followed by a live webcast for investors, analysts and media at 09:00 CET hosted by CEO Fredrik Ruben and CFO Linda Tybring; presentation materials and a recording will be posted on the company website. The announcement reiterates Dynavox's role as parent of Tobii Dynavox, with more than 1,000 employees serving 65+ countries and products that include AI-based speech synthesis in over 30 languages, but provides no financial figures or guidance in the invitation.

Analysis

Market structure: Dynavox (DYVOX) is positioned as a specialist winner—companies with clinical-grade AAC hardware + AI TTS software can expand pricing power and recurring revenue versus commodity tablet providers. Payers and funders (government/insurers) are the choke-point; stable reimbursement sustains demand, while funding cuts would immediately compress revenue growth. Expect modest share gains in specialist rehab & pediatric niches over 12–24 months, but limited near-term impact on large med‑tech incumbents.

Risk assessment: Immediate (days) risk is elevated IV and headline sensitivity around the Feb 5 webcast; short-term (weeks) risk centers on guidance and any funding-news that can swing revenue ±20–30%. Tail risks: regulatory constraints on AI voice synthesis (privacy/deepfake rules), major reimbursement policy changes in key markets, or a component supply shock; each could generate >50% downside for a small-cap like DYVOX. Hidden dependency: outcomes hinge on funding-success metrics (number/value of grants/coverage approvals) that management may disclose.

Trade implications: Event-driven: small pre-release positions and volatility plays are highest odds — liquidity permitting, buy a measured long (1–2% NAV) or a debit straddle sized to 0.5–1% NAV centered on Feb 5 to capture a directional surprise. Pair trade: long DYVOX vs short TOBII.ST (Tobii) if you believe execution/recurring revenue differentiation will show in guidance; target 3–6 month horizon, tighten stops at 15–20%. Rotate capital into med‑device/AI-health ETFs (IHI + XLV overweight by 1–2%) if results confirm recurring revenue growth.

Contrarian angles: Consensus may under-price the value of personalized AI voices and funding expertise—if management quantifies recurring ARPU or conversion rates, upside could be 30–50% over 6–12 months. Conversely, the market could be underestimating reimbursement vulnerability; a pragmatic play is option-based exposure to cap downside while keeping asymmetric upside. Historical parallel: small-cap med‑tech catalysts often move 30–100% on clearer recurring revenue paths or major funding wins; absence of such disclosures could leave DYVOX rangebound.

Key Decisions for Investors

• Establish a small pre-webcast long in DYVOX (ticker DYVOX) sized 1–2% of NAV ahead of the Feb 5 presentation; set stop-loss at 20% and a target partial take-profit at +30% and full exit at +50% within 3–6 months if management reports clear ARPU/recurring revenue growth.
• If options are tradable/liquid, buy a Feb 19 or Mar monthly straddle sized to 0.5–1.0% of NAV to capture volatility around the Feb 5 webcast; cap max premium exposure and plan to close within 7–14 days post-webcast if IV collapses.
• Enter a relative-value pair: long DYVOX (1% NAV) vs short TOBII.ST (1% NAV) for 3–6 months to play execution and recurring‑revenue differentiation; tighten combined portfolio stop at 15% loss and reassess on next quarter results.
• Overweight medical‑device/AI‑health exposure by shifting 1–2% NAV from consumer electronics to IHI (iShares U.S. Medical Devices ETF) and XLV for 6–12 months if Dynavox confirms funding/follow‑through; cut exposure if guidance flags reduced reimbursement/coverage.